A New Na(V)1.7 Mutation in an Erythromelalgia Patient

Mark Estacion,Yang,Sulayman D. Dib-Hajj,Lynda Tyrrell,Zhimiao Lin,Yong Yang,Stephen G. Waxman
DOI: https://doi.org/10.1016/j.bbrc.2013.01.079
IF: 3.1
2013-01-01
Biochemical and Biophysical Research Communications
Abstract:Gain-of-function missense mutations of SCN9A gene, which encodes voltage-gated sodium channel Na(v)1.7, alter channel's biophysical properties causing painful disorders which are refractory to pharmacotherapy in the vast majority of patients. Here we report a novel SCN9A mutation (ca.T3947C) in exon 20 in a 9 year old patient, not present in 200 ethnically-matched control alleles; the mutation substitutes the invariant valine 1316 residue within DIII/S5 by alanine (V1316A). Voltage-clamp studies show that Na(v)1.7 V1316A mutation hyperpolarizes activation (-9 mV), and enhances response to ramp stimuli (3-fold), changes that are predicted to cause hyperexcitability of DRG neurons. V1316A also hyperpolarizes steady-state slow-inactivation (-9.9 mV), which is predicted to attenuate the effect of this mutation on DRG neuron firing. These changes are consistent with previously characterized Erytheromelalgia associated mutations of Na(v)1.7. (C) 2013 Elsevier Inc. All rights reserved.
What problem does this paper attempt to address?